Latest news

Press releases and statements about HIV and related topics

NAT statement on universal availability to HIV prevention medication PrEP

Friday, October 4, 2019

NAT statement on universal availability to HIV prevention medication PrEP

Kat Smithson, Director of Policy at (National AIDS Trust), said:

“NAT stands alongside the doctors who deliver the services to provide PrEP, in calling for it to be universally available to all who need it.”

“The cases of people acquiring HIV while waiting for PrEP in England, show what the impact of limiting access in any way to this drug is for individuals – and for public health. The Department for Health and Social Care, NHS England and local authorities must work urgently to make routine commissioning a reality sooner rather than later.

“Places are currently available on the IMPACT trial so any individuals interested in taking PrEP should talk to their sexual health clinic about it. If your usual clinic has no spaces, you can talk to and enrol at other clinics.”

Press: contact press@nat.org.uk | 020 7814 6767 with any questions or approaches for comment.

NAT Topic